[{"id":"bb831b25-4b1e-44f8-a3dc-5bc7d5306158","acronym":"","url":"https://clinicaltrials.gov/study/NCT02354261","created_at":"2021-01-18T11:12:06.637Z","updated_at":"2024-07-02T16:36:42.308Z","phase":"Phase 2b","brief_title":"Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)","source_id_and_acronym":"NCT02354261","lead_sponsor":"HedgePath Pharmaceuticals, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/07/2015","start_date":" 08/07/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-08-05"},{"id":"eebab600-0270-4c73-93ad-9585470f5fa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02735356","created_at":"2021-01-18T13:23:41.790Z","updated_at":"2024-07-02T16:37:00.682Z","phase":"Phase 1","brief_title":"Topical Itraconazole in Treating Patients With Basal Cell Cancer","source_id_and_acronym":"NCT02735356","lead_sponsor":"Jean Yuh Tang","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/05/2016","start_date":" 05/05/2016","primary_txt":" Primary completion: 09/19/2017","primary_completion_date":" 09/19/2017","study_txt":" Completion: 10/10/2017","study_completion_date":" 10/10/2017","last_update_posted":"2019-04-11"}]